136-150 of 239
The Potential of Immunotherapy in Type 1 Diabetes
Diabetes DiscourseThe Potential of Immunotherapy in Type 1 Diabetes
Matthias von Herrath, MD
Steven Edelman, MD
Nancy Bohannon, MD
Steven Edelman, MD
Interventions Targeting Impaired Glucose Tolerance
Diabetes DiscourseInterventions Targeting Impaired Glucose Tolerance
Robert Henry, MD
Steven Edelman, MD
The ARBITER 6-HALTS Trial: Clinical Implications
Heart MattersThe ARBITER 6-HALTS Trial: Clinical Implications
Christopher Cannon, MD
Jack Lewin, MD
How Will Pharmacogenomics Play a Role in Diabetes Therapy?
Diabetes DiscourseHow Will Pharmacogenomics Play a Role in Diabetes Therapy?
Joseph Ma, PharmD
Steven Edelman, MD
DPP-4 Inhibitors: A New Class of Medications
Diabetes DiscourseDPP-4 Inhibitors: A New Class of Medications
Lisa Kroon, PharmD, CD
Steven Edelman, MD
- advertisement
FDA Patient Safety News: Helping Healthcare Professionals Protect Patients
Focus on PharmacyFDA Patient Safety News: Helping Healthcare Professionals Protect Patients
Charles Turck, PharmD, BCPS, BCCCP
The Importance of Immunizations for Diabetic Patients
Diabetes DiscourseThe Importance of Immunizations for Diabetic Patients
Sarah Lorentz, PharmD
Candis Morello, PharmD, CDE
Drug Delivery Systems in the Management of Diabetes
Diabetes DiscourseDrug Delivery Systems in the Management of Diabetes
Candis Morello, PharmD, CDE
Brookie Best, PharmD
Sodium-Glucose Transporters: A New Class of Diabetes Medications
Diabetes DiscourseSodium-Glucose Transporters: A New Class of Diabetes Medications
Steven Edelman, MD
Vivian Fonseca, MD, FRCP
Do Incretins Play An Important Role In the Cardiovascular System?
Diabetes DiscourseDo Incretins Play An Important Role In the Cardiovascular System?
John Buse, MD, PhD
Steven Edelman, MD
Jack Grider, PhD
Mark DeLegge, MD
- advertisement
Point/Counterpoint: Treatment of IBS With Antibiotics
GI InsightsPoint/Counterpoint: Treatment of IBS With Antibiotics
William Chey, MD
Mark DeLegge, MD
Mark Pimentel, MD
New Developments in Incretins and SGLT Inhibitors
Diabetes DiscourseNew Developments in Incretins and SGLT Inhibitors
Robert Henry, MD
Steven Edelman, MD
Steven Edelman, MD
Candis Morello, PharmD, CDE